Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPWARD seizure risk study of enzalutamide in metastatic castration-resistant prostate cancer
2013-003022-92Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Primary endpoint: Confirmed seizure rate during 4-month treatment. Started Dec 2013; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-003022-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003022-92.